Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes

Donevan, 1993, GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses, Neuron, 10, 51, 10.1016/0896-6273(93)90241-I Lodge, 1993, Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655, Eur. J. Pharmacol., 244, 193, 10.1016/0922-4106(93)90027-7 May, 1993, Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures, J. Neurochem., 60, 1171, 10.1111/j.1471-4159.1993.tb03272.x Oksenberg, 1992, A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors, Nature, 360, 161, 10.1038/360161a0 Patneau, 1993, Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate, J. Neurosci., 13, 3496, 10.1523/JNEUROSCI.13-08-03496.1993 Tarnawa, 1990, Electrophysiological studies with a 2,3-bensodiazepine muscle relaxant: GYKI 52466, Eur. J. Pharmacol., 167, 193, 10.1016/0014-2999(89)90579-7 Tsuzuki, 1992, Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam, Mol. Brain Res., 16, 105, 10.1016/0169-328X(92)90199-L Zorumski, 1992, A benzodiazepine recognition site associated with the non-NMDA glutamate receptor complex, Neuron, 10, 61, 10.1016/0896-6273(93)90242-J